t(8;21)(q22;q22) RUNX1/RUNX1T1

2016-05-01   Wilma Kroes  , Wilma Kroes  

1.Department of Clinical Genetics, Leiden University Medical Center, Leiden; Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands. [email protected]; [email protected]
2.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Disease

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) is part of the Group of AML with recurrent genetic abnormalities.

Phenotype stem cell origin

M2 mostly, rarely: M1 or M4

Epidemiology

Annual incidence: 1/106; 5% of AML, 10% of prior AML M2 (FAB classification). The most frequent anomaly in chilhood AML; seen in children and adults: mean age 30yrs, rare in elderly patients.

Clinics

Myeloid sarcomas may be present at presentation.
Atlas Image
Translocation t(8;21) is found in 5-12% of AML. Among the non-random chromosomal aberrations observed in AML, t(8;21)(q22;q22) is one of the best known and usually correlates with AML M2, with well defined and specific morphological features. The common morphological features include the presence of large blast cells with abundant basophilic cytoplasm, often containing numerous azurophilic granulations; few blasts in some cases show very large granules (pseudo-Chediak-Higashi granules), suggesting abnormal fusion. Auer rods are frequently found. In addition to the large blast cells, there are also some smaller blasts, predominantly found in the peripheral blood. Promyelocytes, myelocytes and mature granulocytes with variable dysplasia are seen in the bone marrow. These cells may show abnormal nuclear segmentation and/or cytoplasmic staining defects including homogeneous pink colored cytoplasm - Text and iconography Courtesy Georges Flandrin 2001.

Cytology

See figure and legend.

Prognosis

Complete remission (CR) in most cases (90%) with relatively long disease-free survival when treated with high dose chemotherapy.

Cytogenetics

Atlas Image
t(8;21)(q22;q22) : cohybridization experiments using dJ155L8 (RUNX1T1) and dJ1107L6 (RUNX1 ); note the splitting of RUNX1 and colocalization on der(8) with RUNX1T1 - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics.

Cytogenetics molecular

Cases with cryptic molecular translocation have been detected --> FISH use may be relevant.

Additional anomalies

Sole anomaly in only 20-30%; additional anomalies: loss of Y or X chromosome in half cases (1 X must be present), del(7q) or -7, +8, del (9q): 10% each.

Variants

Complex t(8;21;Var) involving a (variable) third chromosome have been described in 3%; part from chromosome 21 goes on der(8), part of the 8 on der (Var), and part of Var on der(21); therefore, the crucial event lies on der(8).

Genes Involved and Proteins

Gene name
RUNX1T1 (runt-related transcription factor 1; translocated to, 1 (cyclin D-related))
Location
8q21.3
Dna rna description
Transcription is from telomere to centromere.
Protein description
3 proline rich domains, 2 Zn fingers, and in C-term, a PEST region; tissue restricted expression; nuclear localisation; putative transcription factor.
Gene name
RUNX1 (runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene))
Location
21q22.12
Dna rna description
Transcription is from telomere to centromere.
Protein description
Contains a Runt domain and, in the C-term, a transactivation domain; forms heterodimers; widely expressed; nuclear localisation; transcription factor (activator) for various hematopoietic-specific genes.

Result of the Chromosomal Anomaly

Atlas Image
RUNX1 and RUNX1T1 breakpoints in the t(8;21) / 5 RUNX1 - 3 RUNX1T1 fusion gene, and FISH - Courtesy Hossein Mossafa.

Description

5 RUNX1 - 3 RUNX1T1; breakpoints: at the very 5 end of RUNX1T1, between exons 5 and 6 in RUNX1.

Detection protocole

Karyotyping, RT-PCR and FISH for cases of typical cell morphology, but apparently without the t(8;21); RT-PCR for minimal residual disease detection

Description

The N-term runt domain from RUNX1 is fused to the 577 C-term residues from RUNX1T1; reciprocal product not detected; probable DNA binding role; the fusion protein retains the ability to recognize the RUNX1 concensus binding site (--> negative dominant competitor with the normal RUNX1) and to dimerize with the CBFb subunit.

Oncogenesis

Probable altered transcriptional regulation of normal RUNX1 target genes.

Highly cited references

Pubmed IDYearTitleCitations
350656802022Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.172
318179112019Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription.150
360686102022ASXL1/2 mutations and myeloid malignancies.129
391775142024Mutational cooperativity of RUNX1::RUNX1T1 isoform 9a and oncogenic NRAS in zebrafish myeloid leukaemia.96
339280202021Characteristics of Cohesin Mutation in Acute Myeloid Leukemia and Its Clinical Significance.87
368743782023Therapy-related core binding factor acute myeloid leukemia.86
332174772021The RUNX1/RUNX1T1 network: translating insights into therapeutic options.83
355630852022Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.82
347661232020Modelling t(8;21) acute myeloid leukaemia - What have we learned?80
277986252016The genomic landscape of core-binding factor acute myeloid leukemias.79
335310672021MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3'UTR.72
370199722023Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.71
334835062021RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia.70
285169572017ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.68
409918492025Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia.67
368457152023Mitochondrial gene expression signature predicts prognosis of pediatric acute myeloid leukemia patients.66
263617932015Overexpression and knockout of miR-126 both promote leukemogenesis.65
341251732021Tumor suppressor function of Gata2 in acute promyelocytic leukemia.64
356626932022CNST is Characteristic of Leukemia Stem Cells and is Associated With Poor Prognosis in AML.64
392430822024Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia.62
359028722022RUNX1T1 function in cell fate.61
378417552023CSF3R T618I Collaborates With RUNX1-RUNX1T1 to Expand Hematopoietic Progenitors and Sensitizes to GLI Inhibition.61
377905242023Functional Characterization of Cooperating MGA Mutations in RUNX1::RUNX1T1 Acute Myeloid Leukemia.55
384541212024Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.55
369167802023RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification.54
366135122022AML1-ETO-Related Fusion Circular RNAs Contribute to the Proliferation of Leukemia Cells.54
342006302021DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML).53
408291682025Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.52
359739832022Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.52
265958132016PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.51
338365812021Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.51
364420872022Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.47
403078962025CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.47
350081062022Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia.45
392729672024Minimal Requirements for Cancer Initiation: A Comparative Consideration of Three Prototypes of Human Leukemia.45
300933962018ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion.45
406124092025Cellular hierarchy for understanding heterogeneity of acute myeloid leukaemia with t(8;21)/RUNX1-RUNX1T1.44
353267052022CDK6 Degradation Is Counteracted by p16(INK4A) and p18(INK4C) in AML.42
424220072026Unmasking hidden high risk in RUNX1::RUNX1T1 pediatric AML: Development of a novel prognostic model.42
318967822020The clinical mutatome of core binding factor leukemia.40
407849292025t(8;21)AML patients with RUNX1e6::RUNX1T19a splice variant have poor prognosis.37
380172992024Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.37
362915672022Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the Prognosis for Acute Myeloid Leukemia.33
369394022023Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study.33
403040772025Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia.33
313643092019High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.33
321155722020ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells.32
272520132016ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.31
327576862020Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1.29
398579932025PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia.28
349212232021Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.25
388025932024Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.25
302815972018Eprobe mediated RT-qPCR for the detection of leukemia-associated fusion genes.23
368333232023Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia.20
357658762022Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1.20
397350122024Characterization of Acute Myeloid Leukemia With RUNX1/RUNX1T1 Gene Rearrangement: Clinical, Hematological, and Morphological Features.19
406475342025KDM6A Variants Increased Relapse Risk in Adult Acute Myeloid Leukemia.19
385280802024Differential prognostic values of the three AKT isoforms in acute myeloid leukemia.17
341480542021RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner.15
376210712023Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report.15
396912582024RUNX1::CBFA2T2 rearranged acute myeloid leukemia transformed from JAK2 V617F mutated primary myelofibrosis.14
306236232019Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification.13
338161052021Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion.13
401194662025Dynamin2 mutations in newly diagnosed acute myeloid leukemia: clinical characteristics, and prognostic significance.11
371015512023Pediatric chronic myeloid leukemia in myeloid blast crisis.10
386339252024RUNX1::RUNX1T1 Acute Myeloid Leukemia Cytogenetically Showing t(6;8)(p23;q22).8
403293582025CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial.7
375191082023Hemophagocytic Lymphohistiocytosis in RUNX1::RUNX1T1 Positive AML with Blast Count Below 20%.4
400094982025Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.0
392647252024Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells.0
391796702024STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells.0
220325822011Core-binding factor acute myeloid leukemia.0
398644662025Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions.0
351523502022UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8.0
312811492019[Genetic abnormalities in AML].0
366536962023Comprehensive molecular understanding of pediatric acute myeloid leukemia.0
364768862022[Molecular Genetic Characteristics of Acute Myeloid Leukemia Patients with CBFβ-MYH11 Positive].0
308465082019More than a fusion gene: the RUNX1-RUNX1T1 AML.0
298728842018Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.0
409310472025Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.0
381753762023Mixed-phenotype acute leukemia, T/megakaryoblastic: does it really exist?0
416894672026Differential Prognosis and Transplant Strategies in CBF-AML With RUNX1::RUNX1T1 Versus CBFβ::MYH11 Fusions.0
359005422022Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 - A comprehensive cytogenetic profiling of three cases with review of literature.0
384697802024AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.0
371023022023TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.0
347397012022Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.0
249763382014RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells.0
379250562024Automated Deep Learning-Based Diagnosis and Molecular Characterization of Acute Myeloid Leukemia Using Flow Cytometry.0
408287792025Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.0
360442982023Clinical and Cytogenetic Characteristics of Children With Leukemia 20-Year Retrospective Study.0
243429492014Pontin is a critical regulator for AML1-ETO-induced leukemia.0
419669162026SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?0
395351622024A RUNX1: RUNX1T1 AML with a simultaneous false positive KMT2A rearrangement: FISH interpretation pitfalls.0
391826712024Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies.0
391915102024WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.0
352644982022[A favorable clinical course of acute myeloid leukemia with t (6;21;8)(p23;q22;q22)].0
256357582015Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.0
385698612024[Veno-venous extracorporeal membrane oxygenation for capillary leak syndrome during induction chemotherapy in acute myeloid leukemia].0
428554732026Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML.0
426293902026Oncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness.0

Bibliography

No bibliography items were found for this article.

Summary

Fusion gene

RUNX1/RUNX1T1
Atlas Image
t(8;21)(q22;q22) G- banding (left) - Courtesy Jean-Luc Lai and Alain Vanderhaegen (top) and Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap http://www.slh.wisc.edu/cytogenetics (middle and below); R- banding (middle) - above: Jean Loup Huret; 2nd row: - Courtesy Christiane Charrin; 3rd and 4th row: - Courtesy Roland Berger. Right: FISH - Courtesy Hossein Mossafa.

Citation

Wilma Kroes ; Wilma Kroes

t(8;21)(q22;q22) RUNX1/RUNX1T1

Atlas Genet Cytogenet Oncol Haematol. 2016-05-01

Online version: http://atlasgeneticsoncology.org/haematological/1019/t(8

Historical Card

1997-09-01 t(8;21)(q22;q22) RUNX1/RUNX1T1 by  Jean-Loup Huret,Jean-Loup Huret 

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France